OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort
Robert W Aldridge, Alexei Yavlinsky, Vincent Nguyen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 29
Robert W Aldridge, Alexei Yavlinsky, Vincent Nguyen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Victoria Hall, Sarah Foulkes, Ferdinando Insalata, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 13, pp. 1207-1220
Open Access | Times Cited: 623
Victoria Hall, Sarah Foulkes, Ferdinando Insalata, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 13, pp. 1207-1220
Open Access | Times Cited: 623
Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort
Sakir Ahmed, Pankti Mehta, Aby Paul, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 6, pp. 868-874
Open Access | Times Cited: 73
Sakir Ahmed, Pankti Mehta, Aby Paul, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 6, pp. 868-874
Open Access | Times Cited: 73
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Isaac Yeboah Addo, Frederick Dadzie, Sylvester Reuben Okeke, et al.
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 46
Isaac Yeboah Addo, Frederick Dadzie, Sylvester Reuben Okeke, et al.
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 46
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases
Michael D. Kappelman, Kimberly N. Weaver, Xian Zhang, et al.
The American Journal of Gastroenterology (2021) Vol. 117, Iss. 3, pp. 462-469
Closed Access | Times Cited: 40
Michael D. Kappelman, Kimberly N. Weaver, Xian Zhang, et al.
The American Journal of Gastroenterology (2021) Vol. 117, Iss. 3, pp. 462-469
Closed Access | Times Cited: 40
Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study
Madhumita Shrotri, Ellen Fragaszy, Vincent Nguyen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 34
Madhumita Shrotri, Ellen Fragaszy, Vincent Nguyen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 34
Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Chapin S. Korosec, Suzan Farhang‐Sardroodi, David W. Dick, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 34
Chapin S. Korosec, Suzan Farhang‐Sardroodi, David W. Dick, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 34
Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates
Nawal Al Kaabi, Abderrahim Oulhaj, Subhashini Ganesan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Nawal Al Kaabi, Abderrahim Oulhaj, Subhashini Ganesan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
The Lancet Healthy Longevity (2022) Vol. 3, Iss. 7, pp. e470-e480
Open Access | Times Cited: 29
Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
The Lancet Healthy Longevity (2022) Vol. 3, Iss. 7, pp. e470-e480
Open Access | Times Cited: 29
Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers – the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol
Sarah K. Wallace, Victoria Hall, André Charlett, et al.
BMJ Open (2022) Vol. 12, Iss. 6, pp. e054336-e054336
Open Access | Times Cited: 27
Sarah K. Wallace, Victoria Hall, André Charlett, et al.
BMJ Open (2022) Vol. 12, Iss. 6, pp. e054336-e054336
Open Access | Times Cited: 27
SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
Chin Shern Lau, Soon Kieng Phua, Ya Li Liang, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 331-331
Open Access | Times Cited: 23
Chin Shern Lau, Soon Kieng Phua, Ya Li Liang, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 331-331
Open Access | Times Cited: 23
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination
Moritz M. Hollstein, Lennart Münsterkötter, Michael P. Schön, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2381-2392
Open Access | Times Cited: 21
Moritz M. Hollstein, Lennart Münsterkötter, Michael P. Schön, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2381-2392
Open Access | Times Cited: 21
COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates
Nihar Ranjan Dash, Hiba Jawdat Barqawi, Anas A. Obaideen, et al.
Journal of Epidemiology and Global Health (2023) Vol. 13, Iss. 1, pp. 67-90
Open Access | Times Cited: 11
Nihar Ranjan Dash, Hiba Jawdat Barqawi, Anas A. Obaideen, et al.
Journal of Epidemiology and Global Health (2023) Vol. 13, Iss. 1, pp. 67-90
Open Access | Times Cited: 11
Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
Angelos Hatzakis, Andreas Karabinis, Sotirios Roussos, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 285-285
Open Access | Times Cited: 16
Angelos Hatzakis, Andreas Karabinis, Sotirios Roussos, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 285-285
Open Access | Times Cited: 16
Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants
David Peterhoff, Sebastian Einhauser, Stephanie Beileke, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 324-324
Open Access | Times Cited: 14
David Peterhoff, Sebastian Einhauser, Stephanie Beileke, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 324-324
Open Access | Times Cited: 14
Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 2020 to September 2021
Victoria Hall, Sarah Foulkes, Ferdinando Insalata, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19
Victoria Hall, Sarah Foulkes, Ferdinando Insalata, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19
Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults
Janna R. Shapiro, Rosemary Morgan, Sean X. Leng, et al.
Frontiers in Aging (2022) Vol. 3
Open Access | Times Cited: 11
Janna R. Shapiro, Rosemary Morgan, Sean X. Leng, et al.
Frontiers in Aging (2022) Vol. 3
Open Access | Times Cited: 11
SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron
Sheila F. OʼBrien, Niamh Caffrey, Qilong Yi, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2336-2336
Open Access | Times Cited: 11
Sheila F. OʼBrien, Niamh Caffrey, Qilong Yi, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2336-2336
Open Access | Times Cited: 11
Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose
Alexei Yavlinsky, Sarah Beale, Vincent Nguyen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Alexei Yavlinsky, Sarah Beale, Vincent Nguyen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)
Oliver Stirrup, Maria Krutikov, Gokhan Tut, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 11, pp. 1877-1881
Open Access | Times Cited: 7
Oliver Stirrup, Maria Krutikov, Gokhan Tut, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 11, pp. 1877-1881
Open Access | Times Cited: 7
Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose
Alexei Yavlinsky, Sarah Beale, Vincent Nguyen, et al.
Wellcome Open Research (2022) Vol. 7, pp. 181-181
Open Access | Times Cited: 6
Alexei Yavlinsky, Sarah Beale, Vincent Nguyen, et al.
Wellcome Open Research (2022) Vol. 7, pp. 181-181
Open Access | Times Cited: 6
Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2– seropositive individuals
Edgar Ruz Fernandes, Mônica Taminato, Juliana de Souza Apostólico, et al.
Journal of Allergy and Clinical Immunology Global (2023) Vol. 2, Iss. 2, pp. 100083-100083
Open Access | Times Cited: 3
Edgar Ruz Fernandes, Mônica Taminato, Juliana de Souza Apostólico, et al.
Journal of Allergy and Clinical Immunology Global (2023) Vol. 2, Iss. 2, pp. 100083-100083
Open Access | Times Cited: 3
Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 study
Lisa Seekircher, Zoltán Bánki, Janine Kimpel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Lisa Seekircher, Zoltán Bánki, Janine Kimpel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Breakthrough COVID-19 infections – Analyzing our experience
Aneela Hussain, Samreen Sarfaraz, Sabiha Anis, et al.
Pakistan Journal of Medical Sciences (2023) Vol. 39, Iss. 5
Open Access | Times Cited: 1
Aneela Hussain, Samreen Sarfaraz, Sabiha Anis, et al.
Pakistan Journal of Medical Sciences (2023) Vol. 39, Iss. 5
Open Access | Times Cited: 1
Comparative effectiveness of ChAdOx1 versus BNT162b2 vaccines against SARS-CoV-2 infections in England and Wales: A cohort analysis using trial emulation in the Virus Watch community data
Vincent Nguyen, Alexei Yavlinsky, Sarah Beale, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Vincent Nguyen, Alexei Yavlinsky, Sarah Beale, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Duration of vaccine effectiveness against SARS-CoV2 infection, hospitalisation, and death in residents and staff of Long-Term Care Facilities (VIVALDI): a prospective cohort study, England, Dec 2020-Dec 2021
Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
